| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:50 UTC |
|---|
| Update Date | 2022-03-07 02:51:42 UTC |
|---|
| HMDB ID | HMDB0014669 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Lercanidipine |
|---|
| Description | Lercanidipine is only found in individuals that have used or taken this drug. It is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Lercanidipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. |
|---|
| Structure | COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1 InChI=1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3 |
|---|
| Synonyms | | Value | Source |
|---|
| Lercanil | Kegg | | Zanidip | HMDB | | Biohorm brand OF lercanidipine hydrochloride | HMDB | | Lercadip | HMDB | | Lerdip | HMDB | | Lercanidipine hydrochloride | HMDB | | Methyl-1,1-dimethyl-2-(N-(3,3-diphenylpropyl)-N-methylamino)ethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | HMDB |
|
|---|
| Chemical Formula | C36H41N3O6 |
|---|
| Average Molecular Weight | 611.7272 |
|---|
| Monoisotopic Molecular Weight | 611.299536059 |
|---|
| IUPAC Name | 3-{1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
|---|
| Traditional Name | lercanidipine |
|---|
| CAS Registry Number | 100427-26-7 |
|---|
| SMILES | COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1 |
|---|
| InChI Identifier | InChI=1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3 |
|---|
| InChI Key | ZDXUKAKRHYTAKV-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as quinazolines. Quinazolines are compounds containing a quinazoline moiety, which is made up of two fused six-member aromatic rings, a benzene ring and a pyrimidine ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Diazanaphthalenes |
|---|
| Sub Class | Benzodiazines |
|---|
| Direct Parent | Quinazolines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Quinazoline
- Secondary aliphatic/aromatic amine
- Toluene
- Aryl chloride
- Aryl halide
- Monocyclic benzene moiety
- Benzenoid
- Organosulfonic acid amide
- Organic sulfonic acid or derivatives
- Vinylogous amide
- Aminosulfonyl compound
- Tertiary carboxylic acid amide
- Sulfonyl
- Organosulfonic acid or derivatives
- Amino acid or derivatives
- Carboxamide group
- Lactam
- Carboxylic acid derivative
- Secondary amine
- Azacycle
- Organic oxide
- Organosulfur compound
- Organooxygen compound
- Organonitrogen compound
- Organochloride
- Organohalogen compound
- Amine
- Organopnictogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.00016 g/L | Not Available | | LogP | 6.4 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections| Adduct Type | Data Source | CCS Value (Å2) | Reference |
|---|
| [M+H]+ | CBM | 249.8 | 30932474 |
|
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 8.17 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 16.7428 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.61 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 60.6 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2756.2 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 203.5 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 256.4 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 177.6 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 98.5 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 628.2 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 756.7 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 179.5 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1460.9 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 694.3 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1784.1 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 473.7 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 458.4 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 176.1 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 115.0 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.7 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Lercanidipine,1TMS,isomer #1 | COC(=O)C1=C(C)N([Si](C)(C)C)C(C)=C(C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C2=CC=CC=C2)C1C1=CC=CC([N+](=O)[O-])=C1 | 4076.3 | Semi standard non polar | 33892256 | | Lercanidipine,1TMS,isomer #1 | COC(=O)C1=C(C)N([Si](C)(C)C)C(C)=C(C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C2=CC=CC=C2)C1C1=CC=CC([N+](=O)[O-])=C1 | 3087.9 | Standard non polar | 33892256 | | Lercanidipine,1TMS,isomer #1 | COC(=O)C1=C(C)N([Si](C)(C)C)C(C)=C(C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C2=CC=CC=C2)C1C1=CC=CC([N+](=O)[O-])=C1 | 5485.5 | Standard polar | 33892256 | | Lercanidipine,1TBDMS,isomer #1 | COC(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(C)=C(C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C2=CC=CC=C2)C1C1=CC=CC([N+](=O)[O-])=C1 | 4339.1 | Semi standard non polar | 33892256 | | Lercanidipine,1TBDMS,isomer #1 | COC(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(C)=C(C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C2=CC=CC=C2)C1C1=CC=CC([N+](=O)[O-])=C1 | 3362.0 | Standard non polar | 33892256 | | Lercanidipine,1TBDMS,isomer #1 | COC(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(C)=C(C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C2=CC=CC=C2)C1C1=CC=CC([N+](=O)[O-])=C1 | 5415.2 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Lercanidipine GC-MS (Non-derivatized) - 70eV, Positive | splash10-000i-2191010000-9a91ea6a126944a1a4fb | 2017-09-01 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lercanidipine 10V, Positive-QTOF | splash10-03di-0000009000-9d9d3cd84299b9a1b718 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lercanidipine 20V, Positive-QTOF | splash10-00di-0000019000-b7c19cb600de37512b6b | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lercanidipine 40V, Positive-QTOF | splash10-0006-5094013000-61550404c96e9879a052 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lercanidipine 10V, Negative-QTOF | splash10-03di-0000009000-c5578a9d7353dd125399 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lercanidipine 20V, Negative-QTOF | splash10-03di-0000009000-93862893f933ac09e4de | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lercanidipine 40V, Negative-QTOF | splash10-006x-4092013000-f3bb297f4ce55e9fbe12 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lercanidipine 10V, Negative-QTOF | splash10-03di-0000119000-0687db4621b20c64d0bc | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lercanidipine 20V, Negative-QTOF | splash10-0329-5897346000-a2e4782ffaec352368fc | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lercanidipine 40V, Negative-QTOF | splash10-0002-9500010000-35785b7411b57538ca96 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lercanidipine 10V, Positive-QTOF | splash10-01q9-0937146000-3dbff6a5bec63ea95406 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lercanidipine 20V, Positive-QTOF | splash10-000t-0942011000-5b5db8b5b9de4bd20d10 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lercanidipine 40V, Positive-QTOF | splash10-014i-1920000000-573f0fda3422bc5dde78 | 2021-09-23 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Agrawal R, Marx A, Haller H: Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens. 2006 Jan;24(1):185-92. [PubMed:16331117 ]
- Martinez ML, Lopes LF, Coelho EB, Nobre F, Rocha JB, Gerlach RF, Tanus-Santos JE: Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol. 2006 Jan;47(1):117-22. [PubMed:16424795 ]
- Lin TH, Voon WC, Yen HW, Huang CH, Su HM, Lai WT, Sheu SH: Lercanidipine and losartan effects on blood pressure and fibrinolytic parameters. Kaohsiung J Med Sci. 2006 Apr;22(4):177-83. [PubMed:16679299 ]
|
|---|